Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor.
about
Aptamers: A Feasible Technology in Cancer ImmunotherapyFrom selection hits to clinical leads: progress in aptamer discoveryAptamers: A promising chemical antibody for cancer therapyGeneration of Aptamers with an Expanded Chemical RepertoireNucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical SensingCrystal Structure of Interleukin-6 in Complex with a Modified Nucleic Acid LigandAntibody- and aptamer-strategies for GvHD prevention.Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic AgentsLarge-scale serum protein biomarker discovery in Duchenne muscular dystrophyThe Toolbox for Modified Aptamers.In vitro selection technologies to enhance biomaterial functionality.DNA display of folded RNA libraries enabling RNA-SELEX without reverse transcription.Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys.DNA-Catalyzed Amide HydrolysisSelection of DNA aptamers with two modified bases.Analysis of ATP and AMP binding to a DNA aptamer and its imidazole-tethered derivatives by surface plasmon resonance.Trends in aptamer selection methods and applications.Status and Prospects of Aptamers as Drug Components.Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.Aptamers Against Pro- and Anti-Inflammatory Cytokines: A Review.An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo.Recent Advances in Aptamers Targeting Immune System.Influence of 5-N-carboxamide modifications on the thermodynamic stability of oligonucleotides.Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes.Nucleobase modification by an RNA enzyme.A Novel PEGylation Method for Improving the Pharmacokinetic Properties of Anti-Interleukin-17A RNA Aptamers.Nucleic Acid Aptamers: Emerging Applications in Medical Imaging, Nanotechnology, Neurosciences, and Drug Delivery.Pharmacokinetic Properties of DNA Aptamers with Base Modifications.Chemical modification improves the stability of the DNA aptamer GBI-10 and its affinity towards tenascin-C.Key Aspects of Nucleic Acid Library Design for in Vitro Selection.Molecular modeling and SPRi investigations of interleukin 6 (IL6) protein and DNA aptamers.Crystal structures of thrombin in complex with chemically modified thrombin DNA aptamers reveal the origins of enhanced affinity.Evolution of sequence-defined highly functionalized nucleic acid polymers.
P2860
Q26740303-29E4EEDB-85A1-453B-80AC-244076C73023Q26752799-8D5A4E31-8531-4B13-B3BD-01E2F9F47387Q26766832-2AD72051-43DC-42F2-9ACF-271C2CBF1914Q26782794-B82D5E25-E246-4CFA-9DEF-8D27DBFA93E8Q26825644-8C503F74-744E-4A79-B0B5-4841E1896C51Q27681282-0AB459BB-89B9-4447-913B-E516A8009EACQ34885269-AA17ED47-8D30-4A6C-BCBD-FD180E8E9C97Q35309726-4AA897F3-C1DC-4889-8388-77DB4F816F26Q35740280-8D19F8E5-F9D0-47DE-9211-78BACFF6529BQ35852997-2C37705C-DEB8-4AAD-988C-300E6586202BQ36020230-4EE97D59-D63C-4FB5-A0FC-BD39F3197C9CQ36285843-0230B9ED-20B1-4403-A428-C880CF785975Q36579912-036C84B6-D034-4E09-BD86-092A664C8310Q36619856-D68F99AB-3A79-4B9D-BAE3-DBBBC5C8ADBEQ37711632-EB3C2574-F977-4134-8E1F-2954A3F72AC1Q38297362-9F9A7BF1-2645-4058-A050-2572CDCB768EQ38298067-C9EA7896-A4D2-4425-9320-D63206B47BD2Q38488502-6BF4981C-1926-4AE9-A81B-7AF0DC23C8B5Q38504825-F646A584-5900-411F-88CE-52026985CEC9Q38791725-05E96D79-B589-42DB-AFC9-232E4BFEB110Q38931171-1C5E15BF-7AC2-44E3-B59B-9101E326D3D8Q38945150-36FF0E57-F4AF-436E-BC7C-6868A277D208Q40464660-F17A52C4-D2BD-44BF-8B75-2D19D9D9BC98Q41573492-570CD6AB-8B00-40B7-BF36-2F8A0F5F1649Q41840024-D77DDC3A-237E-46C6-BACD-1B8289C602A1Q42321077-263DB85B-5501-48DE-A038-B02D9A8CF3B6Q47104247-B21DEDFB-527D-429F-920F-057DC71493B8Q47109727-EB23625E-2468-4EB7-AFE8-DF37BA55EAA7Q48354970-9ADFEF0F-63B5-413D-84D1-5734B9CACB22Q50867707-A23417FD-7AA5-41CC-BE11-FB6FF9946D43Q50954695-D095F18D-A95D-4C6D-85DA-12FD3133EA45Q52312646-5AFE045D-EA12-46E0-89E4-7F89A93FC020Q52673150-E4A853B6-4A89-4017-8860-315361CB1C20
P2860
Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Chemically modified DNA aptame ...... n with interleukin-6 receptor.
@en
type
label
Chemically modified DNA aptame ...... n with interleukin-6 receptor.
@en
prefLabel
Chemically modified DNA aptame ...... n with interleukin-6 receptor.
@en
P2093
P2860
P356
P1476
Chemically modified DNA aptame ...... n with interleukin-6 receptor.
@en
P2093
Bharat Gawande
Daniel J Schneider
Ikuo Murakami
Jeffrey D Carter
Masafumi Shibamori
Masahiro Muraguchi
Masao Hirota
Michael Vrkljan
Nebojsa Janjic
P2860
P304
P356
10.1074/JBC.M113.532580
P407
P577
2014-01-12T00:00:00Z